AbbVie Inc ABBV:NYSE

RT Quote | Last NASDAQ LS, VOL From CTA | USD

Last | 12:32 PM EDT

159.33

-2.39 (-1.48%)

Volume

2,281,198

52 week range

130.96 - 182.89

Open162.17
Day High162.44
Day Low158.12
Prev Close161.72
52 Week High182.89
52 Week High Date03/12/24
52 Week Low130.96
52 Week Low Date06/28/23

Key Stats

Market Cap282.117B
Shares Out1.77B
10 Day Average Volume5.69M
Dividend6.20
Dividend Yield3.89%
Beta0.59
YTD % Change2.71

KEY STATS

Open162.17
Day High162.44
Day Low158.12
Prev Close161.72
52 Week High182.89
52 Week High Date03/12/24
52 Week Low130.96
52 Week Low Date06/28/23
Market Cap282.117B
Shares Out1.77B
10 Day Average Volume5.69M
Dividend6.20
Dividend Yield3.89%
Beta0.59
YTD % Change2.71

RATIOS/PROFITABILITY

EPS (TTM)2.72
P/E (TTM)58.59
Fwd P/E (NTM)14.27
EBITDA (TTM)25.413B
ROE (TTM)34.90%
Revenue (TTM)54.318B
Gross Margin (TTM)66.45%
Net Margin (TTM)8.97%
Debt To Equity (MRQ)573.21%

EVENTS

Earnings Date07/25/2024(est)
Ex Div Date04/12/2024
Div Amount1.55
Split Date-
Split Factor-

Latest On AbbVie Inc

Healthy Returns: Humira sales are plunging, but AbbVie has two successorsMay 1, 2024CNBC.com
Jim Cramer's quick thoughts on 5 stocks: Chevron, Snap, Intel, AbbVie and ColgateApril 26, 2024CNBC.com
Monday’s rapid fire: Chevron, Snap, Intel, Abbvie and ColgateApril 26, 2024CNBC.com
Stocks making the biggest moves premarket: Alphabet, Microsoft, Intel and moreApril 26, 2024CNBC.com
Can a new batch of tech earnings rescue the market? Here are the factors at playApril 25, 2024CNBC.com

Content From Our Affiliates

AbbVie price target lowered to $180 from $195 at BMO CapitalApril 29, 2024TipRanks
AbbVie price target lowered to $191 from $196 at Morgan StanleyApril 29, 2024TipRanks
Analysts’ Top Healthcare Picks: AbbVie (ABBV), Wave Life Sciences (WVE)April 29, 2024TipRanks
Buy Rating Affirmed: AbbVie’s Strong Performance and Positive Growth OutlookApril 29, 2024TipRanks
Buy Rating Reaffirmed for AbbVie: Future Growth Beyond Humira’s CompetitionApril 29, 2024TipRanks

Profile

AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica, Venclexta/Venclyxto, Epkinly and Elahere; aesthetics products, which include Botox Cosmetic, The Juvederm Collection of...

Richard Gonzalez

Executive Chairman of the Board

Robert Michael CPA

Chief Executive Officer, Director

Scott Reents

Chief Financial Officer, Executive Vice President

Perry Siatis

Executive Vice President, General Counsel, Company Secretary

Nicholas Donoghoe M.D.

Executive Vice President, Chief Business and Strategy Officer

Address

1 N Waukegan Rd

North Chicago, IL

60064

United States

https://www.abbvie.com/

Top Peers

SYMBOL	LAST	CHG	%CHG
MRK Merck & Co Inc	128.73	-0.07	-0.05%
AZN AstraZeneca PLC	76.03	-0.38	-0.50%
NVS Novartis AG	97.28	-0.22	-0.23%
PFE Pfizer Inc	27.91	+0.73	+2.67%
RHHBY Roche Holding AG	29.25	-0.50	-1.68%